Patents Assigned to EmendoBio Inc.
-
Patent number: 11666641Abstract: The present invention provides a non-naturally occurring composition comprising a CRISPR nuclease comprising a sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3 or a nucleic acid molecule comprising a sequence encoding the CRISPR nuclease.Type: GrantFiled: April 30, 2020Date of Patent: June 6, 2023Assignee: EMENDOBIO INC.Inventors: David Baram, Lior Izhar, Asael Herman, Liat Rockah, Nadav Marbach-Bar, Nurit Meron, Joseph Georgeson
-
Publication number: 20230122086Abstract: The present invention provides a non-naturally occurring composition comprising a CRISPR nuclease comprising a sequence having at least 95% identity to the amino acid sequence selected from the group consisting of SEQ ID NOs: 1-8 or a nucleic acid molecule comprising a sequence encoding the CRISPR nuclease.Type: ApplicationFiled: June 4, 2021Publication date: April 20, 2023Applicant: EmendoBio Inc.Inventors: Lior Izhar, Liat Rockah, Nadav Marbach Bar, Nurit Meron
-
Publication number: 20220387515Abstract: Methods for inactivating in a cell a mutant allele of the elastase, neutrophil expressed gene (ELANE gene) gene having a mutation associated with severe congenital neutropenia (SCN) or cyclic neutropenia (CyN) and which cell is heterozygous at one or more polymorphic sites selected from the group consisting of: rs10424470, rs4807932, rs10414837, rs376107533, rs3761010, rs351108, rs3826946, rs10413889, rs3761007, rs10409474, rs3761005, rs351107, rs3761001, rs740021, rs781452480, rs371057361, rs570466264, rs1041904080, rs7250194, rs17216649, rs199720952, rs6510983, rs17223066, rs7255385, rs9749274, rs111361200, rs112639467, rs141213775, rs28591229, rs10469327, rs3834645, rs1683564, rs71335276, and rs8107095, the method comprising introducing to the cell a composition comprising: a CRISPR nuclease or a sequence encoding the CRISPR nuclease; and a first RNA molecule comprising a guide sequence portion having 21-30 nucleotides, wherein a complex of the CRISPR nuclease and the first RNA molecule affects a douType: ApplicationFiled: November 5, 2020Publication date: December 8, 2022Applicant: EmendoBio Inc.Inventors: David Baram, Lior Izhar, Asael Herman, Rafi Emmanuel, Liat Rockah, Nadav Marbach Bar, Michal Golan Mashiach, Joseph Georgeson
-
Publication number: 20220307057Abstract: RNA molecules comprising a guide sequence portion having 17-25 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-44348 and compositions, methods, and uses thereof.Type: ApplicationFiled: April 14, 2020Publication date: September 29, 2022Applicant: EmendoBio Inc.Inventors: David Baram, Lior Izhar, Asael Herman, Rafi Emmanuel, Michal Golan Mashiach, Joseph Georgeson
-
Publication number: 20220298495Abstract: The present invention provides a novel gene editing composition comprising at least one fusion protein, which comprises a retrotransposon-encoded protein portion linked to a CRISPR nuclease portion, and an RNA template molecule comprising an insert template sequence.Type: ApplicationFiled: June 12, 2020Publication date: September 22, 2022Applicant: EmendoBio Inc.Inventors: Lior Izhar, Noam Diamant, Yuliya Zilberman
-
Publication number: 20220267777Abstract: RNA molecules comprising a guide sequence portion having 17-25 contiguous nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-49516 and compositions, methods, and uses thereof.Type: ApplicationFiled: July 10, 2020Publication date: August 25, 2022Applicant: EmendoBio Inc.Inventors: David Baram, Lior Izhar, Asael Herman, Rafi Emmanuel, Michal Golan Mashiach, Joseph Georgeson
-
Publication number: 20220213456Abstract: The present invention provides a non-naturally occurring composition comprising a CRISPR nuclease comprising a sequence having at least 95% identity to the amino acid sequence selected from the group consisting of SEQ ID NOs: 1-4 or 149-166 or a nucleic acid molecule comprising a sequence encoding the CRISPR nuclease.Type: ApplicationFiled: April 30, 2020Publication date: July 7, 2022Applicant: EmendoBio Inc.Inventors: David Baram, Lior Izhar, Asael Herman, Liat Rockah, Nadav Marbach-Bar, Nurit Meron, Joseph Georgeson
-
Publication number: 20220202913Abstract: The present invention provides a non-naturally occurring composition comprising a CRISPR nuclease comprising a sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3 or a nucleic acid molecule comprising a sequence encoding the CRISPR nuclease.Type: ApplicationFiled: April 30, 2020Publication date: June 30, 2022Applicant: EmendoBio Inc.Inventors: David Baram, Lior Izhar, Asael Herman, Liat Rockah, Nadav Marbach-Bar, Nurit Meron, Joseph Georgeson
-
Publication number: 20220154157Abstract: The present invention is directed to, inter glia, composition and methods for genome editing. Specifically, a non-naturally occurring SpCas9 variant having an amino acid substitution at position K929, H930, or at both position K929 and H930.Type: ApplicationFiled: February 4, 2020Publication date: May 19, 2022Applicant: EmendoBio Inc.Inventors: David Baram, Lior Izhar, Asael Herman, Liat Rockah, Nadav Marbach Bar, Rafi Emmanuel
-
Publication number: 20220136013Abstract: RNA molecules comprising a guide sequence portion having 17-25 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ NOs 1-37365 and compositions, methods, and uses thereof.Type: ApplicationFiled: February 25, 2020Publication date: May 5, 2022Applicant: EmendoBio Inc.Inventors: David Baram, Lior Izhar, Asael Herman, Rafi Emmanuel, Michal Golan Mashiach, Joseph Georgeson
-
Publication number: 20220098621Abstract: RNA molecules comprising a guide sequence portion having 17-25 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs 1-20465 and compositions, methods, and uses thereof.Type: ApplicationFiled: February 4, 2020Publication date: March 31, 2022Applicant: EmendoBio Inc.Inventors: David Baram, Lior Izhar, Asael Herman, Rafi Emmanuel, Michal Golan Mashiach, Joseph Georgeson
-
Patent number: 11274288Abstract: The present invention relates to compositions and methods for increasing the rate of nuclease-mediated site specific insertions of donor DNA sequence to the genome via recombination. More specifically, the method utilizes a non-naturally occurring nuclease-homology directed repair (HDR) protein chimeras for genome editing applications. Physically tethering the activity of a DNA nuclease to an HDR protein results in significant increase in the fraction of nuclease induced DNA breaks that are repaired by homologous recombination and provides higher accuracy and specificity of genome editing.Type: GrantFiled: February 15, 2017Date of Patent: March 15, 2022Assignee: EMENDOBIO INC.Inventors: David Baram, Lior Izhar, Noam Diamant, Rafi Emmanuel
-
Publication number: 20220064635Abstract: RNA molecules comprising a guide sequence portion having 17-25 nucleotides in the sequence of 20-22 contiguous nucleotides set forth in any one of SEQ ID NOs: 1-12655 and compositions, methods, and uses thereof.Type: ApplicationFiled: January 6, 2020Publication date: March 3, 2022Applicant: EmendoBio Inc.Inventors: David Baram, Asael Herman, Rafi Emmanuel, Michal Golan Mashiach, Joseph Georgeson
-
Publication number: 20210371857Abstract: The present invention relates to compositions and methods for increasing the rate of site specific insertion of a donor DNA sequence to the genome. More specifically, the method introduces a donor DNA template containing at least one transcription factor binding site to a cell in order to favor specific insertion of a donor template sequence at a target site by homology directed repair (HDR).Type: ApplicationFiled: October 30, 2017Publication date: December 2, 2021Applicant: EmendoBio Inc.Inventors: David Baram, Lior Izhar, Rafi Emmanuel
-
Publication number: 20210363547Abstract: Methods for inactivating in a cell a mutant allele of the elastase, neutrophil expressed gene (ELANE gene) gene having a mutation associated with severe congenital neutropenia (SCN) or cyclic neutropenia (CyN) and which cell is heterozygous at one or more polymorphic sites selected from the group consisting of: rs10414837, rs3761005, rs1683564, rs9749274, rs740021, rs201048029, rs199720952, rs28591229, rs71335276, rs58082177, rs3826946, rs10413889, rs761481944, rs3761008, rs10409474, rs3761007, rs17216649, rs10469327, rs8107095, rs10424470 and rs78302854, the method comprising introducing to the cell a composition comprising: a CRISPR nuclease or a sequence encoding the CRISPR nuclease; and a first RNA molecule comprising a guide sequence portion having 17-20 nucleotides, wherein a complex of the CRISPR nuclease and the first RNA molecule affects a double strand break in the mutant allele of the ELANE gene the method optionally further comprising introduction of a second RNA molecule comprising a guideType: ApplicationFiled: May 6, 2019Publication date: November 25, 2021Applicant: EMENDOBIO INC.Inventors: David Baram, Lior Izhar, Asael Herman, Rafi Emmanuel, Michal Golan Mashiach, Joseph Georgeson
-
Publication number: 20210207119Abstract: The present invention relates to compositions and methods for increasing the rate of nuclease-mediated site specific insertions of donor DNA sequence to the genome via recombination. More specifically, the method utilizes a non-naturally occurring nuclease-homology directed repair (HDR) protein chimeras for genome editing applications. Physically tethering the activity of a DNA nuclease to an HDR protein results in significant increase in the fraction of nuclease induced DNA breaks that are repaired by homologous recombination and provides higher accuracy and specificity of genome editing.Type: ApplicationFiled: February 15, 2017Publication date: July 8, 2021Applicant: EMENDOBIO INC.Inventors: David Baram, Lior Izhar, Noam Diamant, Rafi Emmanuel
-
Publication number: 20210155929Abstract: Methods for inactivating in a cell a mutant allele of the elastase, neutrophil expressed gene (ELANE gene) gene having a mutation associated with severe congenital neutropenia (SCN) or cyclic neutropenia (CyN) and which cell is heterozygous at one or more polymorphic sites selected from the group consisting of: rs10424470, rs4807932, rs10414837, rs376107533, rs3761010, rs10413889, rs3761007, rs10409474, rs3761005, rs351107, rs3761001, rs740021, rs781452480, rs371057361, rs570466264, rs1041904080, rs7250194, rs17216649, rs199720952, rs6510983, rs17223066, rs7255385, rs112639467, rs141213775, rs28591229, rs10469327, rs3834645, rs1683564, rs71335276, and rs8107095, the method comprising introducing to the cell a composition comprising: a CRISPR nuclease or a sequence encoding the CRISPR nuclease; and a first RNA molecule comprising a guide sequence portion having 17-30 nucleotides, wherein a complex of the CRISPR nuclease and the first RNA molecule affects a double strand break in the mutant allele of theType: ApplicationFiled: November 5, 2020Publication date: May 27, 2021Applicant: EmendoBio Inc.Inventors: David Baram, Lior Izhar, Asael Herman, Rafi Emmanuel, Michal Golan Mashiach, Joseph Georgeson
-
Publication number: 20210130804Abstract: Methods for inactivating in a cell a mutant allele of the elastase, neutrophil expressed gene (ELANE gene) gene having a mutation associated with severe congenital neutropenia (SCN) or cyclic neutropenia (CyN) wherein the mutant allele is selected from the group consisting of the ELANE mutants set forth in Table 1, the method comprising introducing to the cell a composition comprising: a CRISPR nuclease or a sequence encoding the CRISPR nuclease; and a first RNA molecule comprising a guide sequence portion having 17-30 nucleotides, wherein a complex of the CRISPR nuclease and the first RNA molecule affects a double strand break in the mutant allele of the ELANE gene the method optionally further comprising introduction of a second RNA molecule comprising a guide sequence portion capable of complexing with a CRISPR nuclease, wherein the complex of the second RNA molecule and CRISPR nuclease affects a second double strand break in the ELANE gene.Type: ApplicationFiled: November 5, 2020Publication date: May 6, 2021Applicant: EmendoBio Inc.Inventors: David Baram, Lior Izhar, Asael Herman, Rafi Emmanuel, Liat Rockah, Nadav Marbach-Bar, Michal Golan Mashiach, Joseph Georgeson
-
Publication number: 20210032663Abstract: RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID NOs: 1-1313 and compositions, methods, and uses thereof.Type: ApplicationFiled: March 22, 2019Publication date: February 4, 2021Applicant: EMENDOBIO INC.Inventors: David Baram, Lior Izhar, Asael Herman, Rafi Emmanuel, Michal Golan Mashiach, Joseph Georgeson
-
Publication number: 20200332287Abstract: RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID NOs: 1-1990 and compositions, methods, and uses thereof.Type: ApplicationFiled: November 28, 2018Publication date: October 22, 2020Applicant: EmendoBio Inc.Inventors: Lior Izhar, David Baram, Joseph Georgeson, Michal Golan-Mashiach, Asael Herman, Rafi Emmanuel